Collection
Melanoma
A collection of recent articles on melanoma from the American Journal of Clinical Dermatology and Targeted Oncology
Articles (37 in this collection)
-
-
DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma
Authors (first, second and last of 13)
-
-
Relationship of Histopathologic Parameters and Gene Expression Profiling in Malignant Melanoma
Authors
-
Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies
Authors (first, second and last of 7)
-
Global Incidence, Mortality, Risk Factors and Trends of Melanoma: A Systematic Analysis of Registries
Authors (first, second and last of 12)
-
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy
Authors (first, second and last of 14)
-
Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
Authors (first, second and last of 16)
-
-
-
Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors
Authors (first, second and last of 5)
-
-
-
-
Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)
Authors (first, second and last of 20)
-
The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges
Authors (first, second and last of 8)
-
Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment
Authors
-
Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?
Authors (first, second and last of 5)
-
Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma
Authors (first, second and last of 5)
-
Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
Authors (first, second and last of 8)
-
-
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Authors (first, second and last of 20)
-
A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping
Authors (first, second and last of 17)
-
An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions
Authors (first, second and last of 4)
-
Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences
Authors (first, second and last of 4)
-
-
-
-
Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy
Authors (first, second and last of 6)
-
-
Malignant Melanoma of the Vulva and Vagina: A US Population-Based Study of 1863 Patients
Authors (first, second and last of 6)
-
Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice
Authors (first, second and last of 8)
-
Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma
Authors (first, second and last of 8)
-
-
-
Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives
Authors (first, second and last of 4)
-
